Rilzabrutinib works by inhibiting Bruton's tyrosine kinase, an enzyme involved in B‐cell signaling and activation ultimately reducing the production of autoantibodies, which may be clinically efficacious in PV. This evidence concerns the gene BTK and acquired polycythemia vera.